Q4 2021 13F Holders as of 12/31/2021
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
122M
-
Number of holders
-
14
-
Total 13F shares, excl. options
-
13.1M
-
Shares change
-
+721K
-
Total reported value, excl. options
-
$10.3M
-
Value change
-
-$220K
-
Number of buys
-
8
-
Number of sells
-
-3
-
Price
-
$0.78
Significant Holders of Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) as of Q4 2021
16 filings reported holding TRVI - Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share as of Q4 2021.
Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) has 14 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 13.1M shares
of 122M outstanding shares and own 10.8% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (5.94M shares), TPG GP A, LLC (4.82M shares), ARMISTICE CAPITAL, LLC (1.51M shares), RENAISSANCE TECHNOLOGIES LLC (337K shares), VANGUARD GROUP INC (142K shares), MILLENNIUM MANAGEMENT LLC (121K shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (75K shares), CITADEL ADVISORS LLC (49.8K shares), GEODE CAPITAL MANAGEMENT, LLC (49.1K shares), and WealthTrust Axiom LLC (28.5K shares).
This table shows the top 14 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.